Trial Profile
Enzalutamide in heavily pretreated patients with bone metastatic castration-resistant prostate cancer resistant to androgen biosynthesis inhibitor treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Dec 2015 New trial record